GRAIL (NASDAQ:GRAL) (NASDAQ: GRAL) is a biotechnology company dedicated to the early detection of cancer through a multi-cancer blood test. Leveraging advances in next-generation sequencing, cell-free DNA (cfDNA) analysis and machine learning, GRAIL has developed the Galleri™ test, which aims to identify more than 50 types of cancer at their earliest stages. The company’s platform analyzes methylation patterns in circulating tumor DNA to pinpoint tumor presence and tissue of origin, enabling physicians to pursue timely diagnostic follow-up.
Founded in 2016 as a spin-out from Illumina, GRAIL established its headquarters in Menlo Park, California, with additional research and operations centers in the United Kingdom. From its inception, the company has pursued large-scale clinical programs, including the Circulating Cell-Free Genome Atlas (CCGA) study and the STRIVE study, to validate the performance of its assays in diverse populations. These efforts have driven breakthrough device designations from the U.S. Food and Drug Administration and informed regulatory submissions around the world.
GRAIL collaborates with academic institutions, healthcare systems and research organizations to integrate its technology into clinical pathways. The company has partnerships with leading medical centers and national health services, supporting both observational studies and interventional clinical trials. In addition to its direct-to-physician model, GRAIL is working with payers and health plans to explore reimbursement frameworks that broaden patient access to early-detection screening.
The company is led by a management team of seasoned experts in oncology, genomics and diagnostics, whose combined experience spans biotech innovation and regulatory affairs. With a commitment to data-driven research and global health equity, GRAIL continues to expand its reach, seeking to transform the standard of care for cancer screening and improve outcomes through earlier diagnosis.
